Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Clements

Showing results (301-310 of 320) with videos related to

Pageof 32
Sort By:
The Journal of Infectious Diseases|April 1, 1997
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccinesS Zolla-Pazner, C Alving, R Belshe, et al.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
Protein Engineering, Design & Selection : PEDS|May 16, 2008
Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseasesJ Rogers, R J Schoepp, O Schröder, et al.
AJPM Focus|October 27, 2023
Seroprevalence as an Indicator of Undercounting of COVID-19 Cases in a Large Well-Described CohortKevin M Taylor, Keersten M Ricks, Paul A Kuehnert, et al.
Infection and Immunity|May 1, 1981
Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteersB R Murphy, R M Chanock, M L Clements, et al.
Viruses|December 23, 2023
SARS-CoV-2 Aerosol and Intranasal Exposure Models in FerretsElizabeth E Zumbrun, Samantha E Zak, Eric D Lee, et al.
Atmospheric Environment (Oxford, England : 1994)|March 22, 2021
Deliberating Performance Targets: Follow-on workshop discussing PM<sub>10</sub>, NO<sub>2</sub>, CO, and SO<sub>2</sub> air sensor targetsR M Duvall, G S W Hagler, A L Clements, et al.
The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.
Atmosphere|November 3, 2017
Interpreting Mobile and Handheld Air Sensor Readings in Relation to Air Quality Standards and Health Effect Reference Values: Tackling the ChallengesGeorge M Woodall, Mark D Hoover, Ronald Williams, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Pageof 32

Showing results (301-310 of 320) with videos related to

Sort By:
Pageof 32
The Journal of Infectious Diseases|April 1, 1997
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccinesS Zolla-Pazner, C Alving, R Belshe, et al.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
Protein Engineering, Design & Selection : PEDS|May 16, 2008
Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseasesJ Rogers, R J Schoepp, O Schröder, et al.
AJPM Focus|October 27, 2023
Seroprevalence as an Indicator of Undercounting of COVID-19 Cases in a Large Well-Described CohortKevin M Taylor, Keersten M Ricks, Paul A Kuehnert, et al.
Infection and Immunity|May 1, 1981
Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteersB R Murphy, R M Chanock, M L Clements, et al.
Viruses|December 23, 2023
SARS-CoV-2 Aerosol and Intranasal Exposure Models in FerretsElizabeth E Zumbrun, Samantha E Zak, Eric D Lee, et al.
Atmospheric Environment (Oxford, England : 1994)|March 22, 2021
Deliberating Performance Targets: Follow-on workshop discussing PM<sub>10</sub>, NO<sub>2</sub>, CO, and SO<sub>2</sub> air sensor targetsR M Duvall, G S W Hagler, A L Clements, et al.
The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.
Atmosphere|November 3, 2017
Interpreting Mobile and Handheld Air Sensor Readings in Relation to Air Quality Standards and Health Effect Reference Values: Tackling the ChallengesGeorge M Woodall, Mark D Hoover, Ronald Williams, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Pageof 32